JWMS attributes innovation, reliability, professionalism and development to its core competitiveness. We consider innovation of extreme importance because we would not have been successful currently without innovative investment on R&D and cutting-edge technologies in China and around the world. In addition to the pursuit for innovation, we strive to provide patients with the most professional and reliable products in the area of interventional treatment as well as pursue every market opportunity for sustainable development so that our strategic partners, interventional experts, healthcare professionals, government and all others concerned will familiarize themselves with JWMS with the awareness of the fact that JWMS is a brand and a corporation deserving their long-term trust.
JWMS is growing rapidly and steadily. We will continue to promote the production capacity, reduce production cost and benefit more and more patients who suffer coronary heart disease. The new JWMS industrial park is the largest and advanced manufacturing facility for interventional & ICU medical device in the Asia Pacific Region. The industrial park is designed in accordance with the international standards, with a total floorage of 30,000 m2. JWMS will also establish the R&D center, which will become a global R&D center with the most competitive power dedicated to the design of more new products with high technical content and modern significance and becoming a new milestone in the area of life and health.
Upon the development and expansion, the JWMS' people are all looking forward to a bright future. Their career development is an inalienable part of the enterprise advancement. JWMS offers career path for every people, sets up a platform for long-term development and provides them with diversified training programs. We have established a partnership with local universities on a long-term basis to provide employees with different professional courses and help them to improve personal competency and achieve their career target.
We have been in the area of interventional treatment more than ten years.
We understand patients of coronary heart disease, with about 1500,000 of them using our products.
We are familiar with doctors of interventional treatment and have established the long-term partnership with nearly 1,000 authentic medical institutions globally.
We master the key technology of coronary stent and possess the intellectual property of key technology for drug-eluting stent.
We know about the direction of medical intervention market with an adequate understanding of customer needs.
We have integrated a huge number of clinical study data, which have been included and published by numerous world-class conferences and journals.
We are a highly professional team with members' receiving professional training every year.
We will continue to maintain such professionalism as our unique feature and promote such advantage to a higher level.